Log in
Research into modified Fc regions for therapeutic antibodies has resulted in the development of antibodies with novel and optimised functions. An aglycosylated anti-CD3 antibody called otelixizumab has reached phase 3 clinical trials with GSK and a novel antibody for treatment of fetomaternal alloimmune thrombocytopenia has been tested in human volunteers. The patented technology has been licensed to Pfizer and to GSK for incorporation into their therapeutic antibody programmes with four of these already in clinical trials (tanezumab, ponezumab, RN316 & RN564). Licensing revenue totalling £3.2 million has been returned to the University's company Cambridge Enterprise Ltd in the impact period. In addition, consultancy and advisory services on antibody engineering have been provided to a number of other biopharma companies.
Congenital myasthenic syndromes (CMS) are diseases leading to muscle weakness. They are caused by various gene mutations. However, for many CMS patients with a `limb girdle' pattern of weakness, the gene was unknown, and they were unresponsive to the usual CMS treatments. Research by David Beeson and colleagues has changed this state of affairs. First, they showed that this form of CMS is caused by a mutation in a gene called DOK7. Second, they identified the mechanism by which the mutation causes the disease. Third, they discovered that patients with DOK7 mutations respond to a different class of drug, 03b22 adrenergic receptor agonists. DOK7 mutations are now routinely tested for in clinical practice, and these drugs are standard therapy.
Two books and review/research articles in Italian have disseminated the findings from the underpinning research on creating false autobiographical memories and the dangers of inadequate interviewing techniques. This work has critically increased awareness in the Italian legal system amongst both barristers and judges, to the point of shaping the practice of interviewing witnesses in that country. It has also informed all verdicts on child sexual abuse by the Supreme Court of Cassation.
This case study illustrates the development of novel research materials designed to improve quality of life and performance in different populations. Impact has been achieved through the use of research findings in professional practice, formulation of health-related policies and in the development of new indicators of health and well-being. RCSEP research has been used by international and national health-service organisations (e.g., European League Against Rheumatism, Evidence NHS), industrial establishments (e.g., ArtEZ Conservatoire, Netherlands; Royal Ballet), national governing bodies (British Heart Foundation), and professional bodies (e.g., Dance UK, International Association of Dance Medicine & Science).
Research on the environmental safety and toxicity of nanomaterials in fishes has had a global impact across both government and industry contributing to:
(i) Consensus building on biological effects allowing regulatory agencies/governments to make proper decisions on the hazard of nanomaterials to farmed fish and wildlife.
(ii) Critical evaluation of the internationally agreed process of toxicity testing to determine whether the current legislative test methods are fit for purpose and acceptable to the aquaculture industry.
(iii) Identification of national/international research priorities and policies via work with the OECD and the US Government.
(iv) Influencing government policy to support training and information for industry.
Pioneering research at the University of Chichester lead by Professor Harris provided in 2006 first evidence on the effectiveness of beta-alanine supplementation in augmenting carnosine content in human skeletal muscle. Subsequent studies demonstrated the performance-enhancing effect of beta-alanine supplementation, particularly in high-intensity exercise. The research was exploited by a US company through a number of worldwide patents based on Harris' work achieving sales and license revenues of $4.8M in 2013 fiscal year alone. Beta-alanine supplementation has emerged as a legal means to enhance performance taken up at amateur and elite level sport worldwide; it is having global impact on the sports nutrition industry.
Work by University of Stirling staff has contributed directly to improved wildlife resource management in the Central African region. Innovative research into the status and trends of key wildlife populations, ecological impacts, resource harvests and trade, drivers of resource use and assessing management success have contributed directly to new thinking on the issue, revisions of laws and policy and to success in attracting foreign aid for management issues. Stirling staff members now advise the Government of Gabon on resource management policies, National Park management and biodiversity issues.
The Fault Dynamics Research Group (FDRG) have designed and executed analogue experiments to replicate the 3D/4D geometry of oil and gas exploration targets. The main beneficiaries are the international petroleum industry. The research is "pivotal to British Petroleum's subsurface developments" (R. Humphries BP 2012) in determining the number of multi-million pound wells required to access reserves. FDRG models "changed the way seismic data (was) interpreted" (Chief Scientist, Geoscience Australia 2012) in particular in the NW Australian frontier with "BP Exploration (Alpha)....work program(s) of $600 million" (Chief Scientist, Geoscience Australia 2012).
This case study concerns the impact of Plymouth University research relating to farmed fish diets, which led to changes to EU legislation with respect to two types of ingredients: animal proteins and probiotics. The impact of the reintroduction of certain animal proteins in farmed fish feeds (previously banned to protect human health) and to the authorization of a probiotic as a feed additive, involved industry investment in research, have reduced the environmental impact of farmed fishing, improved competitiveness, enhanced yield and quality and improved fish health and survival.
Heriot-Watt University (HWU) does essential research to underpin testing for market release of over 0.5 billion vaccine doses per annum to fish-farms across Europe. These vaccines prevent established and emerging fish diseases in some 25% of trout and 70% of sea bream and bass production in Europe. These diseases would otherwise compromise security and future expansion of important human food supplies. Vaccines are tested for the UK arm of Merck (USA), representing half the company's fish vaccine product range, four of which are in Merck's top 250 products worldwide. Furthermore, research at HWU on MSD Animal Health (MSDAH) ReleraTM vaccine efficacy against novel emerging strains of enteric red mouth (ERM) disease opened-up new markets in Eastern and Central Europe.